Investigational drug · Phase 3
ASKB589
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Cancer, Gastroesophageal Cancer (GC), Malignant Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "ASKB589"
First trial start
2021
Jan 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASKB589", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Cancer
- Gastroesophageal Cancer (GC)
- Malignant Solid Tumor
- Gastroesophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ASKB589" as an intervention, largest first.
- ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaPivotal-lookingActive, not recruiting
AskGene Pharma, Inc.Industry
NCT06206733 · 780 participants (planned) · Start Jan 25, 2024 · Primary completion Dec 30, 2026
Drug: ASKB589; Oxaliplatin and 3 more · For: Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma
Sites: Beijing, China
- A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid TumorsActive, not recruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
NCT04632108 · 199 participants · Start Jan 28, 2021 · Primary completion Oct 31, 2025
Drug: ASKB589 Injection · For: Malignant Solid Tumor
Sites: Beijing, China; Linyi, China
- ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Active, not recruiting
AskGene Pharma, Inc.Industry
NCT05632939 · 62 participants · Start Feb 21, 2023 · Primary completion Oct 31, 2025
Drug: ASKB589 +CAPOX+Sintilimab/Tislelizumab · For: Gastric Cancer; Gastroesophageal Cancer (GC)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Sequential HIPEC, Claudin18.2-targeted therapy, and CapeOx chemotherapy leading to resolution of peritoneal metastases and curative resection in gastric cancer: a case report and literature review.
Li W, Huang X, Han X, et al. · Front Immunol 2025
- Case Report: A rare case of recurrent ascites after anti-Claudin18.2 antibody therapy for metastatic gastric cancer while responding sustainingly.
Liu J, Jiang D, Lei Q, et al. · Front Oncol 2023
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.